Implantable GLP1-RA Dosing Device for Type 2 Diabetes Rejected by FDA Panel.

Published Date: 23 Sep 2023

An FDA advisory panel unanimously decided against approving an implantable device for delivering the GLP-1 receptor agonist exenatide to people with type 2 diabetes due to safety and other issues.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot